brochure

Document Sample
brochure Powered By Docstoc
					JOIN US
You can join us by investing in the cure and becoming part of the fight against cancer

through sponsorship, individual giving, and attending our fundraising events.




                                                                                         Expect Miracles




Mutual Funds Against Cancer
6 Quail Run, Hingham, MA 02043

Founder & Chairman, Frank Strauss
781.749.6495 fstrauss@MutualFundsAgainstCancer.com

Executive Director, Christina E. Thirkell
617.515.3241 cthirkell@MutualFundsAgainstCancer.com                                          MUTUAL FUNDS AGAINST CANCER
Expect Miracles

                  Table of Contents


                  A letter From our Chairman                 3

                  A Letter From our Foundation Sponsor       4

                  Investing In a Cure                       5-6

                  The Center for Applied Cancer Science    7-10

                  Compounding Interest                    11-12

                  Outstanding Events & Milestones         13-14

                  Mutual Funds Redefined                  15-16

                  One Person, Big Difference              17-18




                                                             2
from our                                              Chairman
    Dear MFAC Supporter:                                                                                                         As a recent cancer survivor, I am poised to know first-hand how challenging it is to be faced with the grim reality that

                                                                                                                                 cancer brings. But I am also one of the fortunate ones and living proof of the critical role that research can play in
    You may not realize it, but fighting cancer is directly related to two subjects you’re already very familiar with—
                                                                                                                                 helping to fight this deadly disease.
    Investing and Leverage. The greatest impediment to developing new cancer treatments is cost. The average expense
    to bring one new cancer-fighting drug to market is a staggering $900 million.                                                The commitment of Mutual Funds Against Cancer and the entire financial community in supporting this

                                                                                                                                 organization is nothing short of amazing. In just a few short years, MFAC has raised millions of dollars for cancer
    Mutual Funds Against Cancer understands this problem and is working to solve it. That is why we’ve chosen to
                                                                                                                                 research. And with its recent pledge of raising $4 million for the Center for Applied Cancer Science (CACS), part of the
    support the Center for Applied Cancer Science (CACS), part of the Belfer Institute for Innovative Cancer Science
                                                                                                                                 Belfer Institute for Innovative Cancer Science at Dana-Farber Cancer Institute, MFAC has set its sights even higher.
    at Dana-Farber Cancer Institute. Doctors and scientists at this revolutionary center utilize the most advanced genetic

    technology available to research the six deadliest and most devastating cancers—colon, brain, lung, pancreatic,              As the foundation sponsor for MFAC, Interactive Data and its employees are dedicated to helping reach, and hopefully

    melanoma, and myeloma. They are developing a more efficient research and development model, providing                        surpass, this objective. We realize the importance of joining together to raise funds that will go directly to help CACS

    significantly more value for each dollar invested. This ability to exponentially leverage each dollar raised will            develop and institute innovative approaches to battling cancer. Interactive Data is honored to support MFAC’s

    dramatically reduce the almost $1 billion it takes to bring a new drug to market and help win the fight against cancer.      assertion that through research, we can “expect miracles” when finding a cure for cancer.


    Today, one in three Americans faces a battle with cancer. Our industry alone has recently suffered from the loss of many     We appreciate your support of MFAC, and look forward to working with you in the coming years to achieve its

    of our friends and loved ones. MFAC has been equally devastated by the losses of co-founder Steve Katzin, Paula              fundraising objectives, and more importantly, to band together and make a difference.

    Pearlstein, and most recently, Greg Cannon and Sharon Gallagher. However, because of the help of people like you,
                                                                                                                                 Best regards,
    we are seeing more and more success stories.


    Two thousand years ago Rabbi Hillel, a moral philosopher, asked, “If not now, when? If not you, who?” You have the

    opportunity to make a difference in the fight and help find a cure. We are fortunate to work in a powerful industry.

    You have the influence; your firm has the affluence—together they can form a powerful combination. I urge you to
                                                                                                                                 Ken Starr
    follow the lead of so many great individuals and firms that have made MFAC and finding a cure for cancer a priority.
                                                                                                                                 Vice President, Interactive Data Pricing and Reference Data
                                                                                                                                 Member of the Board of Directors, Mutual Funds Against Cancer
    Join us by investing in cancer research and reducing the cost of drug development. Together, we can expect miracles.


    Sincerely,




    Frank Strauss
                                                                                                                               from our Foundation
                                                                                                                                                                                                  Sponsor
    Chairman, Mutual Funds Against Cancer




3                                                                                                                                                                                                                                                           4
    Investing in A   Cure
                            How much is it worth to see your kids grow up? Or to celebrate your next birthday—when

                            you’re six. We know you can’t put a price tag on these events, but imagine that the donations

                            you make to Mutual Funds Against Cancer are helping moments like these become a reality

                            for patients and families.



                            Mutual Funds Against Cancer (MFAC) is one of the leading advocates in the fight

                            against cancer within the mutual fund and financial services industries nationwide.

                            All proceeds benefit the Center for Applied Cancer Science (CACS), part of the Belfer

                            Institute for Innovative Cancer Science at Dana-Farber Cancer Institute, one of the

                            leading cancer research facilities in the world. MFAC has raised more than $2.5 million for

                            this cause and will continue to raise funds and awareness until we meet our goal of

                            finding a cure.



                            For more information, visit www.MutualFundsAgainstCancer.com.




5                                                                                                                           6
THE CENTER FOR APPLIED
    CANCER SCIENCE
                         A revolutionary new model for academic medicine, CACS is at the heart of Dana-Farber’s

                         strategic plan to control major forms of cancer within the next ten years. The center

                         exemplifies the sophisticated and systematic approach that is required to solve the enduring

                         puzzle of cancer. It revolves around a multi-disciplinary and multi-institutional scientific

                         collaboration that is guided by the strong and focused leadership of the Dana-Farber

                         Cancer Institute.



                         CACS is creating a drug discovery and development pipeline for six deadly cancers: colon,

                         pancreatic, lung, melanoma (skin), myeloma (blood), and glioblastoma (brain). These cancers

                         take a terrible toll on those they afflict, and cure rates have been limited by few existing

                         effective treatments. The pipeline is a priority in the Institute’s strategic plan for research, the

                         overarching goal of which is to accelerate the development of promising investigational new

                         drugs (INDs) for each of these six diseases. Specifically, CACS scientists are identifying the

                         genes that are integral to both malignancy and its reversal in each cancer, creating antibodies

                         that will interact with and inhibit these targets, and testing each target/antibody

                         interaction on sophisticated preclinical cancer models. Once drug candidates are

                         identified, CACS collaborates with pharmaceutical and biotechnology companies to ensure

                         that promising new drugs are moved into organized and focused clinical trials and then

                         marketed successfully.



                         CACS Mission: To Accelerate the Translation of Scientific Discoveries into New Drugs.




7                                                                                                                               8
Through its drug discovery pipeline, CACS is designed to convert the raw material of basic discovery into drug
development endpoints rapidly and systematically, and bring new treatments to cancer patients faster than ever before.   This will occur through five major activities:


                                                                                                                         Target discovery and validation

                                                                                                                         CACS scientists sequence tumor samples from the six major cancers, develop genomic

                                                                                                                         profiles for each of these cancer types, and identify the specific genes that cause malignancy

                                                                                                                         in each cancer.



                                                                                                                         Bioinformatics and computational science

                                                                                                                         CACS research relies upon new and powerful technologies that bring together biology,

                                                                                                                         information science, and statistics in order to process the huge amounts of data that result

                                                                                                                         from microarray experiments and genomic profiling.




                                                                                                                         Drug development

                                                                                                                         Once genetic data is processed and genuine targets for therapy have been identified,

                                                                                                                         CACS scientists create targeted therapeutic agents that interact with these targets and

                                                                                                                         reverse malignancy.




                                                                                                                         Preclinical models and experimental therapeutics

                                                                                                                         CACS scientists have created refined cancer models that mimic disease progression, enable

                                                                                                                         elucidation of the role of particular genes in malignancy, and provide for rigorous assessment

                                                                                                                         of the effectiveness and toxicity of anticancer drug agents.




                                                                                                                         Collaboration with pharmaceutical and biotechnology companies

                                                                                                                         Once basic discoveries have been converted into promising drug candidates and tested on

                                                                                                                         preclinical models, CACS collaborates with pharmaceutical and biotechnology companies

                                                                                                                         to ensure that promising new drugs are moved into organized and focused clinical trials and

“The Center for Applied Cancer Science represents a new academic construct that, in addition to                          then delivered to mainstream patient care.
deciphering cancer’s complexity and discovering new therapeutic leads,
has an unprecedented opportunity to change the practice of how drugs are discovered and developed.”
                        - Dr. Ron DePinho
9                         Director, The Center for Applied Cancer Science                                                                                                                                                 10
                                                                                     When Frank Strauss founded MFAC, he knew that he and those in the financial community

                                                                                     had an opportunity to give back and help win the fight against cancer. Together, our industry

                                                                                     can use its vast resources and will to take our skill in investing for our clients and focus it




                                                 INTEREST
                                                                                     on investing in a cure.

     COMPOUNDING                                                                                                           PERCENTAGE OF FUNDS
                                                                                                                            Percentage of Funds

                                                                                                                                    Overhead
                                                                                                                                    4.7%
                                                                                                                     Auctions
                                                                                                                        11.4%




                                                                                                       Donations                                            Sponsorships
                                                                                                           20.5%                                            63.4%




                                                                                                       $3,000,000               FUNDRAISING HISTORY


                                                                                                       $2,500,000




                                                                                       AMOUNT RAISED
                                                                                                       $2,000,000



                                                                                                       $1,500,000



                                                                                                       $1,000,000



                                                                                                        $300,000




                                                                                                                    2004     2005      2006          2007       2008          2009

                                                                                                                                              YEAR


                                                                                     In 2007, MFAC announced a more targeted mission: to support the Center for Applied

                                                                                     Cancer Science (CACS), part of the Belfer Institute for Innovative Cancer Science

                                                                                     at Dana-Farber Cancer Institute. All of our proceeds benefit CACS, and we have pledged
        “This has been a great vehicle to                                            to raise $4 million.
       pay tribute to friends and family who fought
          a courageous fight, and to those who are fighting today.”
11                            - Gary Enos
                                                                                                                                                                                       12
                                Executive Vice President, State Street Corporation
                                                                                                         MFAC continues to grow year after year with exciting events and
                                                                                                         initiatives. It is the industry that truly keeps MFAC afloat and has

       Outstanding Events &                                                                              chosen to join our team in the journey to eradicate cancer.




                                    Milestones                                                                                  Expect Miracles Golf Classic
                                                                                                                                Mutual Funds Against Cancer’s cornerstone event hosts more than
                                                                                                                                100 sponsors from the top financial firms and more than 400
                                                                                                                                golfers from the financial community. The Expect Miracles Golf
                                                                                                                                Classic is held every June and has been embraced by the financial
                                                                                                         industry as the industry charity event of the year. The event has been featured in several
                                                                                                         Boston business publications throughout the years.


                                                                                                                                Expect Miracles Wine & Spirits Extravaganza
                                                                                                                                Launched in 2004, The Wine & Spirits Extravaganza takes place
                                                                                                                                every fall in Boston and brings together more than 450 industry
                                                                                                                                executives for an evening of wine tasting, awards, and auctions.


                                                                                                         Partnered Events and Programs
                                                                                                                                5K Challenge
                                                                                                                                In 2006, MFAC launched a 5K Race at NICSA’s annual
                                                                                                                                Technology Summit in Las Vegas. For two years in a row
                                                                                                                                NICSA conference participants have been a part of a fun,
                                                                                                                                relaxing 5K run/walk to benefit Mutual Funds Against Cancer.
                                                                                                         Major firms, including State Street Corp and AT&T, have teamed up for major
                                                                                                         sponsorships of this event. MFAC and NICSA will continue to partner together for
                                                                                                         future initiatives and events.


                                                                                                                                Charity of Choice
                                                                                                                                Mutual Funds Against Cancer was selected as the featured charity
                                                                                                                                at the Institutional Investor’s Mutual Funds Award Gala in NYC
                                                                                                                                three years in a row. This was an honor and has allowed MFAC to
                                                                                                                                not only raise more funds, but also broaden its reach and expand
                                                                                                                                MFAC nationwide to industry leaders.


                                                                                                                                Mutual Funds Against Cancer
                                                                                                                                Rings Opening Bell at NYSE
“There’s a natural affinity between MFAC’s mission and our guests at the Mutual Funds Industry Awards.
                                                                                                                                MFAC was honored to ring the Opening Bell at the New York
       We are excited to be able to help raise awareness of this important cause                                                Stock Exchange on October 8, 2007. This event allowed MFAC
                                           with the most senior players in the industry.”                                       to reach millions in the business and financial arena.

  13                                           - Tracey Redmond                                                                                                                                       14
                                                 Awards Director, Institutional Investor News
                                                                                                       Sponsors and Strategic Partners
                                                                                                       Investment Managers                     Banks, Transfer Agents,
                                                                                                       AIM                                     and Technology Firms
                                                                                                       American Century                        AT&T
                                                                                                       BlackRock

                                                           REDEFINED
                                                                                                                                               Bank of New York Mellon

            MUTUAL FUNDS
                                                                                                       Bridgeway Capital Management            Boston Financial Data Services
                                                                                                       DWS Scudder                             Brown Brothers Harriman
                                                                                                       Eaton Vance Management                  Capital IQ
                                                                                                       Epoch                                   Citi
                                                                                                       Evergreen Investments                   Confluence
                                                                                                       Franklin Templeton Investments          DST Systems
                                                                                                       Independence Investments                Eagle Investment Systems
                                                                                                       John Hancock Financial Services         IGEFI
                                                                                                       Legg Mason                              JPMorgan Chase
                                                                                                       Loomis, Sayles & Company                Northern Trust
                                                                                                       Lord, Abbett                            Omgeo, LLC
                                                                                                       Munder Capital Management               PFPC, Inc.
                                                                                                       Natixis Global Investments              SEI
                                                                                                       Old Mutual Asset Management             State Street Corporation
                                                                                                       Oppenheimer                             SunGard
                                                                                                       PIMCO                                   UMB Fund Services
                                                                                                       Pioneer Investments
                                                                                                       Schroder Investment Management
                                                                                                       Sentinel Investments
                                                                                                       State Street Global Advisors
                                                                                                       T. Rowe Price
                                                                                                       UBS Global Asset Management
                                                                                                       US Trust – Excelsior Funds
                                                                                                       Upromise
                                                                                                       Van Kampen Investments
                                                                                                       XTF



                                                                                                       Professional Services Firms
                                                                                                       Beacon Consulting Group                 KPMG LLP
                                                                                                       Bombardier Flexjet                      Merrill Corporation
                                                                                                       BOWNE / GCom2Solutions                  Morrison & Forester LLC
                                                                                                       Briggs, Bunting & Dougherty             NICSA
                                                                                                       Broadridge Investor Comm. Services      PricewaterhouseCoopers
                                                                                                       Capital Fulfillment Group               Reuters
                                                                                                       Computershare Fund Services             RR Donnelley
                                                                                                       Deloitte                                SalesLink
                                                                                                       Elmec, Inc                              SalesPage
                                                                                                       Ernst & Young                           SimCorp
                                                                                                       George H. Dean Co.                      SMS Vanacore
                                                                                                       Harte-Hanks                             Titan Custom Clothing
                                                                                                       Interactive Data Corporation            Veritude
                                                                                                       Investment Company Institute            WilmerHale
                                                                                                       kasina                                  WinterWyman

“With the tremendous support we receive from the entire mutual fund and financial services industry,
             we’re committed to making sure that finding a cure                                        A special thank you to the following
                                                                                                       firms who have worked alongside MFAC:
                             is only a matter of time.”                                                DiBona, Bornstein & Random
                                                                                                       Teehan + Lax Web Design
15                                           - Frank Strauss                                           Harte-Hanks                                                              16
                                               Chairman, Mutual Funds Against Cancer
                                                                                                       Saltus Press
                      Frank Strauss’ involvement with The Jimmy Fund began in May of 1995 when his mother,




 One Person
                      Sandy, was diagnosed with leukemia. Although cancer strikes more than one out of three

                      Americans, at this point in his life, Frank had yet to be affected. His mother was referred to




     BIG DIFFERENCE
                      the Dana-Farber Cancer Institute where physicians, who gave her a one-in-three chance to

                      survive, saved her life.



                      While at the Dana-Farber, Frank would see child cancer patients come in for their treatments

                      with their parents, whose faces carried the weight of the world. As a new father, Frank found

                      himself caught in the paradox of the miracle of new life and the fear of losing a parent. It was

                      then that he realized he was in the right position, as a part of the financial community, to

                      attract enough resources, bring people together, and make a difference by investing in a cure.



                      Today, MFAC has grown into one of the leading advocates in the fight against cancer.

                      Since its inception, MFAC has continued to grow its partnership with the Jimmy Fund

                      and has become a key contributor to the Center for Applied Cancer Science. New ideas,

                      new technology, and new talent are some of the most vital components in Dana-Farber’s

                      work, and all three require philanthropic support and gifts like those received from

                      Mutual Funds Against Cancer.




                      “As I look ahead, the future certainly looks bright for MFAC. However, my personal goal is

                      that we are out of business ten years from now. With the discovery of the human genome and

                      the utilization of computer models to help the smartest doctors in the world, it truly is just

                      a matter of time until cancer is relegated into the chronic disease category. So when the next

                      generation is told that they have cancer, the next thing they will be told is what pill they need

                      to take to be cured. Then we will know that we have accomplished something together.”



                      Frank Strauss
                      Chairman, Mutual Funds Against Cancer




17                                                                                                                        18

				
DOCUMENT INFO